Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
Authors
Pugh, SBowers, M
Ball, A
Falk, S
Finch-Jones, M
Valle, Juan W
O'Reilly, D
Siriwardena, A
Hornbuckle, J
Rees, M
Rees, C
Iveson, T
Hickish, T
Maishman, T
Stanton, L
Dixon, E
Corkhill, A
Radford, M
Garden, O J
Cunningham, D
Maughan, T
Bridgewater, J
Primrose, J
Affiliation
University Surgery and Cancer Sciences Division, University of Southampton, Southampton General Hospital, Southampton SO16 6YDIssue Date
2016-08-09
Metadata
Show full item recordAbstract
The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival. Details of disease progression are described to further inform the primary study outcome.Citation
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. 2016, 115 (4):420-4 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/bjc.2016.208PubMed ID
27434036Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2016.208